Objective: The aim of our study was to conduct a cohort that demonstrates genetic variations in cytokines genes involved in the physiopathology, the development and the heterogeneity of the clinical course in PD.

Background: Parkinson’s disease (PD) is the second most prevalent neurodegenerative condition following Alzheimer’s disease. It is triggered by the immune system in individuals with genetic susceptibility.

Method: We conducted a retrospective analysis of patient’s data diagnosed with PD at the Charles Nicolle Hospital, in the neurology department (2021-2023). Additionally, we included control subjects in our study. In collaboration with the department of immunology, patients and healthy controls underwent investigations for serum levels of IL-1β and IL-6. Our study focused specifically on genetic cytokines polymorphisms in the development of PD.

Results: Our study included 26 PD patients, with a sex-ratio(M/F)=0.57 and an average age=64.08 years, along with 30 control subjects. With respect to genetic study, in disease group, C allele frequency at Il-1βwas=65.9%, T allele frequency at il-1β was=34.10%, C allele frequency at IL-6 was=19%, and G allele frequency at IL-6 was=81%. Genotype distributions at IL-1 was as follows: CC: 42% in PD versus 40.9% in controls, CT: 28.6% in PD versus 40.9% in controls, and TT: 19% in PD versus 18.2% in controls. Genotype distribution at IL-6 was as follows: CC=4.8% in PD versus 0% in controls, CG=28.6% in PD versus 21.4% in controls, and GG genotype=66.7% in PD versus 78.6% in controls. Our study found no association of neither IL-6 nor IL-1β with PD susceptibility in the Tunisian population.

Conclusion: Our inconsistent results are possibly due to various ethnics of the studied populations, and the eventual presence of other single nucleotide polymorphisms in linkage disequilibrium with those investigated in our study.

References: 1. Nie S, Wang J, Deng Y, Ye Z, Ge Y. Inflammatory microbes and genes as potential biomarkers of Parkinson’s disease. NPJ Biofilms Microbiomes. 2022 Dec 24;8(1):101.
2. Wahner AD, Sinsheimer JS, Bronstein JM, Ritz B. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch Neurol. 2007 Jun;64(6):836–40.
3. Schulte T, Schöls L, Müller T, Woitalla D, Berger K, Krüger R. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson’s disease. Neurosci Lett. 2002 Jun 21;326(1):70–2.
4. McGeer PL, Yasojima K, McGeer EG. Association of interleukin-1 beta polymorphisms with idiopathic Parkinson’s disease. Neurosci Lett. 2002 Jun 21;326(1):67–9.
5. Mattila KM. Association of an interleukin 1B gene polymorphism (-511) with Parkinson’s disease in Finnish patients. J Med Genet. 2002 Jun 1;39(6):400–2.
6. Håkansson A, Westberg L, Nilsson S, Buervenich S, Carmine A, Holmberg B, et al. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson’s disease: IL-6 and ERbeta in Parkinson’s Disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 5;133B(1):88–92.

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/genetic-study-of-polymorphism-of-cytokines-in-parkinsons-disease/